1 / 47

Best of ASCO Gynecologic Oncology

Objectives. Ovarian CancerMaintenance Therapy after First Line MIMOSA First Line: ICON 7 (OS)Recurrent

beck
Download Presentation

Best of ASCO Gynecologic Oncology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Best of ASCO Gynecologic Oncology David M. O'Malley, M.D. Assistant Professor Division of Gynecologic Oncology Department of Obstetrics & Gynecology The James Cancer Center Set A1 – Title SlideSet A1 – Title Slide

    2. Objectives Ovarian Cancer Maintenance Therapy after First Line MIMOSA First Line: ICON 7 (OS) Recurrent – Platinum Sensitive Bev - OCEANS PARPi Screening - PLCO Set A1 – Content SlideSet A1 – Content Slide

    9. Abagovomab is most likely done Concept is strong Disappointing result Maintenance Therapy GOG 212 (taxane versus observation) Pazopanib Multi-target Anti-angiogenesis BIBF 2120 Multi-target Anti-angiogenesis Set A1 – Content SlideSet A1 – Content Slide

    10. Primary Therapy - Bev Set A1 – Content SlideSet A1 – Content Slide

    19. Recurrent Platinum Sensitive Set A1 – Content SlideSet A1 – Content Slide

    28. Bevacizumab First Line +/- Maintenance GOG 218 ICON 7 “High Risk”: suboptimal and stage IV Recurrent Disease OCEANS Set A1 – Content SlideSet A1 – Content Slide

    29. PARPi Set A1 – Content SlideSet A1 – Content Slide

    36. PARPi Which PARPi First line? Maintenance? Recurrent? Single Agent? With cytotoxic? With Bev? Next GOG trial: PARPi versus Bev versus Both Set A1 – Content SlideSet A1 – Content Slide

    37. Screening Set A1 – Content SlideSet A1 – Content Slide

    47. Questions Set A1 – Content SlideSet A1 – Content Slide

    48. Closing SlideClosing Slide

More Related